Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Johnson & Johnson makes $2.1 billion offer to buy out Japan cosmetics firm Ci:z

Published 10/23/2018, 05:58 AM
© Reuters. FILE PHOTO: A Johnson & Johnson building is shown in Irvine, California

By Makiko Yamazaki

TOKYO (Reuters) - U.S. healthcare conglomerate Johnson & Johnson (N:JNJ) said on Tuesday it will buy all outstanding shares of Japanese skincare firm Ci:z Holdings Co Ltd (T:4924) that it does not already own for 230 billion yen ($2.05 billion) in cash.

J&J is betting the deal - which will give it ownership of popular brands such as Dr.Ci:Labo, Labo Labo and Genomer - will help it strengthen its international innovation pipeline.

The purchase adds to a flurry of cosmetics deals in Asia in recent years, as global brands seek to expand in a booming region that includes the $53.5 billion China market by leveraging Asian brands' smart online marketing and fast turnaround times for new products.

France's L'Oreal SA (PA:OREP) agreed to buy South Korean makeup and fashion firm Nanda in May, and Unilever NV (AS:UNc) bought cosmetics firm Carver Korea for $2.7 billion last year. LVMH (PA:LVMH) and Estee Lauder Companies Inc (N:EL) have also invested in South Korean cosmetics firms.

J&J will pay 5,900 yen per Ci:z share, a 55 percent premium over Tuesday's closing price, and also acquire the shares owned by the Japanese firm's founder Yoshinori Shirono, J&J said in a statement.

CIC Corp, the founder's ownership vehicle, is the biggest shareholder of the dermo-cosmetics specialist with a 27.96 percent interest, showed Refinitiv data.

J&J is the second-largest shareholder, owning 19.9 percent through an affiliate since 2016, allowing it to distribute Ci:z's brands outside of Japan. J&J expects the full acquisition will help it leverage the large consumer database of the collagen gel and medical skin products maker.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"This transaction will maximise value creation ... by bringing in an agile innovation model and rapidly accelerating sales through our global commercialization expertise," Jorge Mesquita, worldwide chairman at Johnson & Johnson's consumer division, said in the statement.

J&J, which has been selling businesses such as diabetes care devices to focus on better-performing units and product development, plans to launch the tender offer on Oct. 29.

($1 = 112.3500 yen)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.